RESEARCH TRIANGLE PARK, N.C., July 15, 2022 (GLOBE NEWSWIRE) —
BioCryst Pharmaceuticals, Inc.
(Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 1
st
Annual Hereditary Angioedema Virtual Conference on Wednesday, July 20, 2022, at 10:00 a.m. ET.
The link to a live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at
.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO
®
(berotralstat) is approved in the United States and multiple global markets. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and yellow fever. RAPIVAB
®
(peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at
www.biocryst.com
.
BCRXW
Investor Contact
:
John Bluth
+1 919 859 7910
Media Contact
:
Catherine Collier Kyroulis
+1 917 886 5586
